0001104659-22-120752.txt : 20221121
0001104659-22-120752.hdr.sgml : 20221121
20221121160518
ACCESSION NUMBER: 0001104659-22-120752
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221118
FILED AS OF DATE: 20221121
DATE AS OF CHANGE: 20221121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Drutz David
CENTRAL INDEX KEY: 0001428764
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32587
FILM NUMBER: 221405774
MAIL ADDRESS:
STREET 1: 8601 SIX FORKS ROAD
STREET 2: SUITE 160
CITY: RALEIGH
STATE: NC
ZIP: 27615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Altimmune, Inc.
CENTRAL INDEX KEY: 0001326190
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202726770
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 910 CLOPPER ROAD
STREET 2: SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 2406541450
MAIL ADDRESS:
STREET 1: 910 CLOPPER ROAD
STREET 2: SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
FORMER COMPANY:
FORMER CONFORMED NAME: PHARMATHENE, INC
DATE OF NAME CHANGE: 20071016
FORMER COMPANY:
FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP
DATE OF NAME CHANGE: 20050505
4
1
tm2231089-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-11-18
0
0001326190
Altimmune, Inc.
ALT
0001428764
Drutz David
C/O ALTIMMUNE, INC.,
910 CLOPPER ROAD, SUITE 201S
GAITHERSBURG
MD
20878
1
0
0
0
Common Stock, par value $0.0001
2022-11-18
4
M
0
139
2.4
A
20151
D
Common Stock, par value $0.0001
333
I
See Footnote
Stock Options (option to buy)
2.4
2022-11-18
4
M
0
139
0
D
2022-12-31
Common Stock, par value $0.0001
139
0
D
Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018.
This option is fully vested and exercisable as of the date hereof.
/s/ Richard Eisenstadt, as Attorney-in-Fact
2022-11-21